Kintegral Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.87M | Hold |
160,592
| – | – | 0.31% | 82 |
|
|
2026
Q1 | $4.51M | Sell |
160,592
-7,121
| -4% | -$190K | 0.43% | 57 |
|
|
2025
Q4 | $4.18M | Sell |
167,713
-4,590
| -3% | -$116K | 0.35% | 77 |
|
|
2025
Q3 | $4.39M | Sell |
172,303
-771
| -0.4% | -$19K | 0.37% | 77 |
|
|
2025
Q2 | $4.2M | Sell |
173,074
-261
| -0.2% | -$6.09K | 0.38% | 79 |
|
|
2025
Q1 | $4.39M | Sell |
173,335
-582
| -0.3% | -$15.2K | 0.44% | 70 |
|
|
2024
Q4 | $4.61M | Sell |
173,917
-8,102
| -4% | -$220K | 0.44% | 63 |
|
|
2024
Q3 | $5.27M | Sell |
182,019
-2,385
| -1% | -$69.6K | 0.48% | 60 |
|
|
2024
Q2 | $5.16M | Buy |
184,404
+130,606
| +243% | +$3.6M | 0.49% | 54 |
|
|
2024
Q1 | $1.49M | Sell |
53,798
-168
| -0.3% | -$4.66K | 0.15% | 134 |
|
|
2023
Q4 | $1.55M | Sell |
53,966
-344
| -0.6% | -$10.4K | 0.17% | 130 |
|
|
2023
Q3 | $1.8M | Sell |
54,310
-32
| -0.1% | -$1.13K | 0.22% | 109 |
|
|
2023
Q2 | $1.99M | Hold |
54,342
| – | – | 0.24% | 107 |
|
|
2023
Q1 | $2.22M | Sell |
54,342
-2,919
| -5% | -$126K | 0.29% | 102 |
|
|
2022
Q4 | $2.93M | Sell |
57,261
-9,351
| -14% | -$448K | 0.39% | 88 |
|
|
2022
Q3 | $2.92M | Hold |
66,612
| – | – | 0.4% | 68 |
|
|
2022
Q2 | $3.49M | Buy |
66,612
+1,411
| +2% | +$71.9K | 0.45% | 59 |
|
|
2022
Q1 | $3.38M | Buy |
65,201
+1,459
| +2% | +$75.7K | 0.37% | 65 |
|
|
2021
Q4 | $3.76M | Hold |
63,742
| – | – | 0.39% | 59 |
|
|
2021
Q3 | $2.74M | Hold |
63,742
| – | – | 0.32% | 76 |
|
|
2021
Q2 | $2.5M | Hold |
63,742
| – | – | 0.29% | 83 |
|
|
2021
Q1 | $2.31M | Hold |
63,742
| – | – | 0.3% | 86 |
|
|
2020
Q4 | $2.35M | Sell |
63,742
-3,442
| -5% | -$126K | 0.32% | 77 |
|
|
2020
Q3 | $2.34M | Sell |
67,184
-2,163
| -3% | -$75.8K | 0.35% | 72 |
|
|
2020
Q2 | $2.15M | Hold |
69,347
| – | – | 0.35% | 76 |
|
|
2020
Q1 | $2.15M | Buy |
69,347
+7,759
| +13% | +$264K | 0.42% | 68 |
|
|
2019
Q4 | $2.29M | Hold |
61,588
| – | – | 0.42% | 71 |
|
|
2019
Q3 | $2.1M | Hold |
61,588
| – | – | 0.42% | 71 |
|
|
2019
Q2 | $2.53M | Hold |
61,588
| – | – | 0.51% | 48 |
|
|
2019
Q1 | $2.48M | Sell |
61,588
-2,023
| -3% | -$81K | 0.52% | 50 |
|
|
2018
Q4 | $2.63M | Buy |
+63,611
| New | +$2.64M | 0.78% | 33 |
|
Other funds holding PFE
Kintegral Advisory's PFE Position: Q2 2026 in Review
Kintegral Advisory held its Pfizer (PFE) position steady in Q2 2026 at 160,592 shares worth $3.87M. The position accounts for 0.31% of the portfolio, ranked #82.
Kintegral Advisory first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.27M in Q3 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Kintegral Advisory held 160,592 shares of Pfizer worth $3.87M as of Q2 2026.
- Kintegral Advisory left its Pfizer share count unchanged in Q2 2026.
- Pfizer made up 0.31% of Kintegral Advisory's portfolio in Q2 2026, its #82 holding.
- Kintegral Advisory first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Kintegral Advisory's Pfizer position peaked at $5.27M in Q3 2024.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Kintegral Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.